Open AccessOral Activated Charcoal Adsorbent (AST-120) Ameliorates Chronic Kidney Disease-Induced Intestinal Epithelial Barrier Disruption
Author(s) -
Nosratola D. Vaziri,
Jun Yuan,
Mahyar Khazaeli,
Yuki Masuda,
Hirohito Ichii,
Shuman Liu
Publication year - 2013
Publication title -
american journal of nephrology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 85
eISSN - 1421-9670
pISSN - 0250-8095
DOI - 10.1159/000351171
Subject(s) - oxidative stress , kidney disease , inflammation , occludin , medicine , endocrinology , barrier function , uremia , kidney , systemic inflammation , malondialdehyde , tight junction , chemistry , biology , biochemistry , microbiology and biotechnology
Chronic kidney disease (CKD) impairs intestinal barrier function which by allowing influx of noxious products causes systemic inflammation. We have recently shown that intestinal barrier dysfunction in CKD is due to degradation of epithelial tight junction (TJ) which is, in part, mediated by influx of urea and its conversion to ammonia by microbial urease. We hypothesized that by adsorbing urea and urea-derived ammonia, oral activated charcoal (AST-120) may ameliorate CKD-induced intestinal epithelial barrier disruption and systemic inflammation.